The estimated Net Worth of Alexander G Esterhazy is at least $23.6 mil dollars as of 28 October 2005. Alexander Esterhazy owns over 20,001 units of Cel-Sci stock worth over $23,601 and over the last 20 years Alexander sold CVM stock worth over $0.
Alexander has made over 7 trades of the Cel-Sci stock since 2004, according to the Form 4 filled with the SEC. Most recently Alexander exercised 20,001 units of CVM stock worth $4,400 on 28 October 2005.
The largest trade Alexander's ever made was exercising 40,000 units of Cel-Sci stock on 25 October 2005 worth over $8,800. On average, Alexander trades about 7,467 units every 16 days since 2004. As of 28 October 2005 Alexander still owns at least 20,001 units of Cel-Sci stock.
You can see the complete history of Alexander Esterhazy stock trades at the bottom of the page.
Alexander's mailing address filed with the SEC is 8229 BOONE BLVD, STE 802, VIENNA, VA, 22182.
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten y Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Cel-Sci executives and other stock owners filed with the SEC include: